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A B S T R A C T
Background
Methadone maintenance was the first widely used form of opioid replacement therapy developed to treat heroin dependence, and it
remains the best-researched treatment for this problem. Despite the widespread use of methadone in maintenance treatment for opioid
dependence in many countries, it is a controversial treatment whose effectiveness has been disputed.
Objectives
To evaluate the effects of methadone maintenance treatment (MMT) compared with treatments that did not involve opioid replacement
therapy (i.e., detoxification, offer of drug-free rehabilitation, placebo medication, wait-list controls) for opioid dependence.
Search strategy
We searched all the following databases up to 2001: Cochrane Drugs and Alcohol Review Group Register, the Cochrane Controlled
Trials Register, MEDLINE, EMBASE, Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug Council
of Australia (ADCA) [www.adca.org.au], Australian Drug Foundation (ADF-VIC) [www.adf.org.au], Centre for Education and In-
formation on Drugs and Alcohol (CEIDA) [www.ceida.net.au], Australian Bibliographic Network (ABN), and Library of Congress
databases, available NIDA monographs and the College on Problems of Drug Dependence Inc. proceedings, the reference lists of all
identified studies and published reviews; authors of identified RCTs were asked about other published or unpublished relevant RCTs.
Selection criteria
All randomised controlled clinical trials of methadone maintenance therapy compared with either placebo maintenance or other non-
pharmacological therapy for the treatment of opioid dependence.
Data collection and analysis
Reviewers evaluated the papers separately and independently, rating methodological quality of concealment of allocation, data were
extracted independently for meta-analysis and double-entered.
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Main results
Six studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a total
number of 954 participants. The method of concealment of allocation was inadequate in one study, not clearly described in four
studies, but adequate in a sixth study. Based on the meta-analysis, methadone appeared statistically significantly more effective than
non-pharmacological approaches in retaining patient in treatment (3 RCTs, RR=3.05; 95%CI: 1.75-5.35) and in the suppression of
heroin use (3 RCTs, RR=0.32; 95%CI: 0.23-0.44), but not statistically in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25).
Authors’ conclusions
Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment
and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant
superior effect on criminal activity.
P L A I N L A N G U A G E S U M M A R Y
Methadone maintenance treatment can keep people who are dependent on heroin in treatment programs and reduce their use
of heroin
Methadone is the most widely used replacement for heroin in medically-supported maintenance or detoxification programs. Several
non-drug detoxification and rehabilitation methods are also used to try and help people withdraw from heroin. However the review
found that people have withdrawn from trials when they are assigned to a drug-free program.Consequently, there are no trials comparing
methadonemaintenance treatment with drug-freemethods other thanmethadone placebo trials, or comparing methadonemaintenance
with methadone for detoxification only. These trials show that methadone can reduce the use of heroin in dependent people, and keep
them in treatment programs.
B A C K G R O U N D
Currently, the major form of medical therapy for heroin depen-
dence internationally involves orally administered methadone.
Methadone is an analgesic medication developed to treat pain in
the 1940s. It has been, and is still, prescribed widely for the man-
agement of pain in America, Australia and Europe.
It was in New York in the 1960s, during an increase in heroin
use and heroin dependence, that researchers (Dole 1965; Dole
Nyswander 1967) examined different prescribed opioids to man-
age heroin dependence, and reported that they found that metha-
done was most suitable to the task. They believed that long-term
heroin use caused a permanent metabolic deficiency in the central
nervous system and an associated physiological disease, which re-
quired regular administration of opiates to correct the metabolic
deficiency (Dole 1969 & Nyswander, 1965). The disorder of opi-
oid dependence has been represented in the International Classifi-
cation of Disease of theWorldHealth Organisation. It is a chronic
or long-term and relapsing disorder, and some believe that it re-
quires ongoing maintenance medication.
The aspects of methadone that have led to its use as a substi-
tute drug for heroin include the number of pharmacological fea-
tures of opioids. At the basis of methadonemaintenance treatment
(MMT) is the observation that opioid analgesics can be substi-
tuted for one another (Jaffe 1990). Methadone at adequate doses
(of 20mg to more than 100 mg) prevents or reverses withdrawal
symptoms (Ward 1992), and thus reduces the need to use ille-
gal heroin (Jaffe 1990). Methadone remains effective for approx-
imately 24 hours, requiring a single daily dose rather than the
more frequent administration of three to four times daily which
occurs with the shorter-acting heroin (Jaffe 1990).Methadone can
“block” the euphoric effects of heroin, discouraging illicit use and
thereby relieving the user of the need or desire to seek heroin (Dole
1969). This allows the opportunity to engage in normative activi-
ties, and “rehabilitation” if necessary. Methadone can cause death
in overdosage, like other similar medications such as morphine,
and for this reason it is a treatment which is dispensed under med-
ical supervision and relatively strict rules. In summary, methadone
is a long-acting opioid analgesic with well-understood pharmaco-
logical characteristics which make it suitable for stabilising opioid
dependent patients in a maintenance treatment approach.
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There is evidence that the quality of the therapeutic relationship
with staff in methadone clinics plus the intensity of these ancillary
services, combined with the dose of methadone prescribed will
all act to enhance the outcome for methadone treatment (Ward
1992), although this is not the focus of this review.
Methadone maintenance treatment remains one of the best
researched treatments for opioid dependence (Cooper 1983;
Gerstein 1990; Hargreaves 1983; Mattick 1993; Ward 1992).
It is the only treatment for opioid dependence which has been
clearly demonstrated to reduce illicit opiate use more than either
no-treatment (Dole 1969; Yancovitz 1991), drug-free treatment
(Gunne 1981), placebomedication (Newman 1979; Strain 1993a;
Strain 1993a), or detoxification (Vanichseni 1991) in clinical con-
trolled trials. These trials have been conducted by different research
groups, in markedly differing cultural settings, yet have converged
to provide similar results.
O B J E C T I V E S
The present systematic review aimed to provide an evaluation of
the effectiveness of methadone maintenance treatment on opioid
dependence compared with treatments that did not include an
opioid replacement therapy. The focus of the review is on retention
in treatment, opioid use as measured by objective urine results and
from self-report, as well as criminal activity and patient mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The literature was reviewed for all clinical controlled trials of
MMT against another treatment which does not use opioid re-
placement therapy.
Types of participants
Individuals who were opioid dependent were the target popula-
tion for this review. No distinction was made between those using
heroin and those who have been in methadone treatment prior to
entering the research trial treatment. No restrictions were imposed
in terms of studies of outpatients, inpatients, those with comorbid
states, etc.
Types of interventions
Interventions were included if they used methadone maintenance
therapy (MMT). The MMT interventions were included even
where they also employed other treatments, such as behavioural
therapies or outpatient rehabilitation. The control groups were
treated with placebo medication, withdrawal or detoxification
(with or without ancillary medication), drug-free rehabilitation
treatment (such as therapeutic communities), and no treatment
or wait-list controls.
Types of outcome measures
Outcome measures:
Primary outcomes
1) retention in treatment
2) mortality
3) proportion of urinalysis results positive for heroin (or mor-
phine)
4) self-reported heroin use
5) criminal activity
Secondary outcomes
1) use of other drugs
2) physical health
3) psychological health
Search methods for identification of studies
The search strategy was developed in consultation with a drug and
alcohol research information specialist without language restric-
tions.
We searched:
1. Cochrane Drugs and Alcohol Review Group Register for trials
of methadone maintenance therapy to 2001.
2. Cochrane Controlled Trials Register for trials of methadone
maintenance therapy to 2001.
3. MEDLINE (1966-2001) (OVID) was searched using the
Cochrane Collaboration sensitive search strategies used to identify
randomised trials in conjunction with the following to identify
studies comparing methadone maintenance therapy and no meth-
adone maintenance therapy:
#1 exp methadone
#2 (placebo or withdrawal or detoxification or untreated or no
treatment or drug free or wait list).ti, ab, rw,sh.
#3 exp pain/ or pain.ti, ab, rw, sh.
#4 (1 and 2) not 3
EMBASE (1980-2001) was searched using the following (OVID):
#1 exp methadone/ or exp methadone treatment/ ct (limit to clin-
ical trials)
#2 exp drug dependence or exp substance abuse or exp drug abuse
#3 1 and 2
#4 limit to human
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#5 placebo or withdrawal or untreated of drug free or detoxifica-
tion or wait list
#6 4 and 5
As several drug and alcohol journals are not indexed on the main
electronic databases, Current Contents, Psychlit (-2001), CORK
[www.state.vt.su/adap/cork], Alcohol and Drug Council of Aus-
tralia (ADCA) [www.adca.org.au], Australian Drug Foundation
(ADF -VIC) [www.adf.org.au], Centre for Education and Infor-
mation onDrugs and Alcohol (CEIDA) [www.ceida.net.au], Aus-
tralian Bibliographic Network (ABN), and Library of Congress
databases were* searched for studies and book chapters comparing
methadone maintenance with other treatment.
4. The references of all identified studies and published reviews
were inspected for more trials.
Data collection and analysis
Each potentially relevant study located in the search was obtained
and independently assessed for inclusion by two of three review-
ers. Data extraction for each study was undertaken by the same
two reviewers, again independently. A standardised checklist was
used for data extraction. Disagreement was dealt with by the third
reviewer, acting as a mediator. If unresolved disagreements on in-
clusion, study quality or extraction occurred they were referred to
the editor.
It is generally not the case that these trials were blinded. As such,
methodological quality was assessed by assessment of the randomi-
sation procedure and the likelihood that randomisation was not
biased:
A. Low risk of bias (allocation clearly independent of clinical staff );
B. Moderate risk of bias (some doubt about the independence of
the allocation procedure); and
C. High risk of bias (inadequate separation of randomisation from
clinical staff ).
A standardised effect size was calculated for each study, based on
themain outcomemeasure reported.Where possible (relative risks
and 95% confidence intervals for dichotomous outcomes (reten-
tion) using a random effects model and standardised mean dif-
ferences for continuous outcomes were presented. To assess for
statistical heterogeneity a test of homogeneity was undertaken. A
pooled effect size estimate was derived for each domain of mea-
surement (retention in treatment, urine analysis results for heroin/
morphine ), self-reported heroin use, and criminal activity. The
retention in treatment and urine results were reported as the num-
ber of patients retained or the number with a morphine-positive
urine result at follow-up, a form of reporting that allowed for di-
chotomous analysis of those data.
The results were integrated from the meta-analytic review into a
discussion taking into consideration other publications including
large-scale observational studies, studies of the pharmacology of
methadone, and studies of the effect of MMT on HIV serocon-
version. Convergence of the evidence from the meta-analysis and
the narrative review was taken to indicate a robust conclusion.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
The information provided in the tables present the characteristics
of the excluded and the included studies.
One study was not included. A study by Bale (Bale 1980) was an
attempt to compare methadone against therapeutic community
treatment of detoxification. Because the study failed, no useful
data could be obtained from it for this review.
In total, six studies were included in this review. The first study
by Dole (Dole 1969) was a two group randomised trial where
patients either received methadone or placed on a wait- list. The
second study (Gunne 1981) randomly allocated patients to receive
methadone maintenance or to be allocated to a drug-free rehabil-
itation. None of the patients allocated to drug-free rehabilitation
took up the offer, refusing treatment after they had learnt that they
would not receive methadone. There were two placebo controlled
trials (Newman 1979, Strain 1993a). Finally, there have been two
randomised clinical trials, one assessing methadone maintenance
against methadone detoxification and the other assessing meth-
adone maintenance against a wait-list control (Vanichseni 1991,
Yancovitz 1991).
All studies were assessed to determine whether they provided data
on retention in treatment, code able results from urine analysis,
self-reported drug use (particularly heroin use), criminal activity
and mortality. After reviewing the studies, it was realised that it
was not possible to include urine results for cocaine and benzodi-
azepines as these were not reported in an analysable form for most
studies . Thus, it was not possible to analyse data on either cocaine
or benzodiazepine positive urine from these studies. However, it
was possible to code data on retention in treatment, morphine
positive urine, self-reported heroin use, criminal activity, andmor-
tality.
Risk of bias in included studies
Of the six studies included in this review, two were placebo-con-
trolled trials (Newman 1979, Strain 1993a). Both of these studies
were double-blind but neither of these two studies provided suf-
ficient data to be confident about the concealment of allocation .
The first study conducted by Dole (Dole 1969) seemed to have
inadequate concealment of allocation . The other three studies had
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reasonable concealment, and particularly the Yancovitz (Yancovitz
1991) had good concealment of allocation.
The sample sizes in these studies were sometimes small, in that
two studies having sample sizes of 32 and 34 (Dole 1969; Gunne
1981), respectively. The other four studies had sample sizes ranging
from 100 to 240 (Newman 1979; Vanichseni 1991) patients up
to 247 to 301 patients (Strain 1993a; Yancovitz 1991).
The dosages of methadone used in these studies appears to have
been adequate. In the first study, (Dole 1969) the dose at release
from prison was 35 milligrams but patients were entered into a
community program where blockade doses of approximately 100
milligrams were standard. In the study by Gunne (Gunne 1981)
the doses are not clearly stated. The placebo-controlled study by
Newman (Newman 1979) have an average dose on 97 milligrams
per day. An average of 74 milligrams per day was reported in the
study from Thailand (Vanichseni 1991). Strain (Strain 1993a)
used doses of methadone of 50 and 20 milligrams per day. Finally,
the study by Yancovitz 1991 used a maintenance dose of approxi-
mately 80 milligrams per day. As such, the results from the studies
appear to use moderate to high doses on average.
Data on retention in treatment, self-reported heroin use, criminal
activity, mortality and morphine positive urine were provided in
the studies.
Effects of interventions
1.Selection of Studies/Participants/Interventions
Six studies were included in the review. The participants (n=954)
were from a range of geographic regions including USA, Sweden,
Hong Kong, Thailand and they were largely typical of heroin
dependant individuals, in terms of age and gender characteristics.
In some studies, only males were included but where females were
included the gender distribution was as one would expect with
majority of the participants being male.
As shown in the table of included studies, the interventions gen-
erally lasted for significant time of several weeks up to two years,
although one study only ran for 45 days.
2.Quantitative Analysis
Retention in treatment could be coded from three studies, and
the results showed that methadone has a superior retention rate
compared with control conditions. When compared with placebo
medications and with the wait-list control there was an advantage
in terms of retention for methadone over the control groups (3
studies, 505 patients; RR= 3.05, 95% CI 1.75-5.35). The relative
risk on a random effect model was applied. The chi-square test for
heterogeneity was significant (p=0.018). The examination of the
graphical representation of the relative risks showed that one study
(Newman 1979) did appear to be slightly different from the other
two studies, with higher RR, even though all single RRs where
in the same direction of a positive effect (Vanichseni 1991; Strain
1993a).
Turning to the data frommorphine positive urines, only two stud-
ies (Vanichseni 1991; Yancovitz 1991) provided data which were
usable because of the way inwhich the datawere typically reported.
Specifically, many studies did not provide dichotomous data as to
whether patients had morphine positive urines at the follow-up.
However, the results from the two studies providing data on the
presence/absence of morphine in urine at the follow-up showed
an advantage of methadone above the control conditions (2 stud-
ies, 409 patients, RR= -0.32, 95% CI -0.40 -0.23), in this case
detoxification or wait-list control, in reducing heroin use as shown
by a lack of heroin metabolites in urine.
The results from the objective data on morphine positive urine
were also supported by self-report data from three studies. In
particular, studies from the USA and from Sweden (Dole 1969;
Yancovitz 1991; Gunne 1981) all concurred to show an advantage
formethadone above control in reduction of heroin use as reported
by the patients (3 studies, 230 patients RD=0.32, 95% CI:0.23-
0.44). The test for heterogeneity was not significant, indicating
the results can be interpreted confidently. The results show clearly
an advantage for methadone above the control conditions which
included no treatment, referral to drug-free treatment, or frequent
contact on a waiting list.
The results for the criminal activity variable, available for three
studies, were consistent with the reduction in heroin use, even
though the advantage for methadone beyond control in reducing
criminal activity was not statistically significant (3 studies, 363
patients RR=0.39, 95% CI:0.12-1,25). The test for heterogeneity
was not significant.
Turning finally to the evidence concerning the ability of meth-
adone to prevent deaths, available for three studies, the results
showed a trend in favour on methadone that was not statistically
significant (3 studies, 435 patients RR=0.49, 95%CI: 0.06-4.23).
Other measures (e.g., use of other drugs, physical health, and psy-
chological health) are too infrequently and irregularly reported in
the literature to be usefully integrated in the quantitative review.
D I S C U S S I O N
The results of the meta-analysis indicate that methadone is able
to retain patients in treatment better than the drug-free alterna-
tives (placebo medication, offer of drug-free treatment, detoxifi-
cation, or wait-list control), to suppress heroin use based on mor-
phine (the heroin metabolite) found in urine samples, and patient
self-report. There was a greater reduction in criminal activity and
mortality among the MMT patients, but these differences were
not statistically significant. There is evidence from other literature
showing that mortality is decreased in patients who are in metha-
done treatment.
Interestingly, the results from these six randomised trials all showed
statistically significant positive benefits from methadone treat-
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ment, despite their small sample sizes. Additional support for the
efficacy of methadone maintenance treatment comes from the re-
sults of many observational studies wherein some statistical form
of control has addressed alternative explanations of apparent ef-
fectiveness. These large scale observational studies have generally
supported the results from the randomised clinical trials in show-
ing that methadone maintenance treatment reduces the use of
heroin and decreases criminal activity (Ward 1992). As noted ear-
lier there is a broader international literature showing advantages
for methadone beyond other treatments in terms of reduction of
death (Ward 1992), even though the randomised trial data do not
show this result.
Another relevant outcome to be considered would be seroconver-
sion for HIV, which is the object of a separate Cochrane review in
progress. Methadone maintenance treatment has been shown to
reduce HIV risk taking behaviour (specifically reduction in needle
sharing) and thereby has achieved a reduction in the transmission
of HIV. Consistent with this it has been shown that methadone
maintenance treatment is protective of patients, reducing HIV
infection in geographic locations where HIV had spread rapidly
among injecting drug users who had not entered treatment. We
have commented elsewhere on two large prospective cohort stud-
ies in the USA which found methadone maintenance treatment
protected against HIV infection. This outcome could not be ad-
dressed here as there are no randomised trials of methadone that
have included HIV status as a measure, the evidence coming from
observational studies (Ward 1992).
It is notable that the doses of methadone used in the randomised
clinical trials are probably slightly higher than are being used cur-
rently in routine clinical practice in some parts of the world. This
relative under dosing in clinical practice may lead to a reduction
in the effectiveness of methadone, as the response to methadone
treatment is dose-dependent. In addition, it is important to recog-
nise that methadone treatment in these trials was often provided
with substantial ancillary services. These ancillary services have
included counselling, psycho-social services, medical services and
often psychiatric care. The quality of the therapeutic relationship
with staff in methadone clinics plus the intensity of these ancillary
services, combined with the dose of methadone prescribed will all
act to enhance the outcome for methadone treatment. The extent
that clinical programs move away from such an approach might
be expected to impact on the effectiveness of methadone.
This does not imply that methadone maintenance treatment will
become ineffective. Even allowing for some reduction in effective-
ness when methadone is not provided in the fashion that it has
been in the clinical trials, it is still likely to be effective. The ef-
fects of methadone may be modest, if they are judged by unrealis-
tic expectations of patients can easily achieve enduring abstinence
from opioid drugs. Methadone nonetheless attracts and retains
more patients than alternative treatments, and it does produce
better outcomes amongst those who complete treatment. Metha-
done maintenance appears to provide better outcomes than simple
detoxification programs, where the evidence suggests that short-
term detoxification has no enduring effect on drug use (Mattick
1996).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The implications of the results of the meta-analytic review con-
ducted and reported herein for clinical practice are that metha-
done maintenance treatment is an effective intervention for the
management of heroin dependence. Methadone retains patients
in treatment and reduces heroin use. Methadone should be sup-
ported as a maintenance treatment for heroin dependence.
Implications for research
Overall there are a relatively limited number of randomised clin-
ical trials on the efficacy of methadone treatment compared to
placebo. It does not seem feasible at this stage to conduct further
randomised trials of methadone treatment. However, evidence on
reduction of criminal activity and mortality from clinical trials is
lacking calling for an additional systematic review of observational
studies. Moreover, monitoring of the outcome of standard metha-
done treatment in clinical practice may be important as a research
activity to demonstrate its ongoing effectiveness, or to determine
whether its effectiveness is being compromised through the reduc-
tion of ancillary services or reduction in adequate dose levels.
A number of measures (e.g., of other drug use, physical health,
and psychological health) were too infrequently and irregularly re-
ported in the literature to be usefully integrated in the quantitative
review, but future research might address these important areas.
A C K N OW L E D G E M E N T S
We acknowledge the assistance of the Cochrane Review Group
Coordinating Centre, Rome.
6Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Dole 1969 {published data only}
Dole V, Robinson J, Orraca J, Towns E, Searcy P, Caine E.
Methadone treatment of randomly selected criminal addicts.
New England Journal of Medicine 1969;280:1372–1375.
Gunne 1981 {published data only}
Gunne L, Gronbladh L. The Swedish methadone
maintenance program: A controlled study. Drug and
Alcohol Dependence 1981;7:249–256.
Newman 1979 {published data only}
Newman R, Whitehill W. Double-blind comparison of
methadone and placebo maintenance treatments of narcotic
addicts in Hong Kong. Lancet 1979;September 8:485–488.
Strain 1993a {published data only}
Strain E, Stitzer M, Leibson I, Bigelow G. Dose-response
effects of methadone in the treatment of opioid dependence.
Ann Intern Med 1993;119:23–27.
Vanichseni 1991 {published data only}
Vanichseni S, Wongsuwan B, The Staff of BMA Narcotics
Clinic No.6, Choopanya K, Wongpanich K. A controlled
trial of methadone in a population of intravenous drug
users in Bangkok: implications for prevention of HIV.
International Journal of the Addictions 1991;26(12):
1313–1320.
Yancovitz 1991 {published data only}
Yancovitz S, Des Jarlais D, Peskoe Peyser N, Drew E,
Friedman P, Trigg H, Robinson J. A randomised trial of an
interim methadone maintenance clinic. Am J of Pub Health
1991;81:1185–1191.
References to studies excluded from this review
Bale 1980 {published data only}
Bale R, Van Stone W, Kuldau J, Engelsing T, Elashoff
R, Zarcone V. Therapeutic communities vs methadone
maintenance. A prospective controlled study of narcotic
addiction treatment: design and one year follow-up. Arch
Gen Psych 1980;37:179–193.
Additional references
Cooper 1983
Cooper J, Altman F, Brown, B, Czechowicz D. Research on
the treatment of narcotic addiction: State of the art. Rockville,
MD: National Institute on Drug Abuse, 1983.
Dole 1965
Dole V, Nyswander M. A medical treatment of
diacetylmorphine (heroin) addiction. JAMA 1965;193:
80–84.
Dole Nyswander 1967
Dole V, Nyswander M. Heroin addiction - a metabolic
disease. Arch Internal Medicine 1967;120:19–24.
Gerstein 1990
Gerstein D, Harwood H. Treating drug problems Volume 1:
A study of effectiveness and financing of public and private
drug treatment systems. Washington, DC: National Academy
Press, 1990.
Hargreaves 1983
Hargreaves W. Methadone dosage and duration for
maintenance treatment.. In: J Cooper, F Altman, B Brown,
D Czechowicz editor(s). Research on the treatment of narcotic
addiciton: State of the art. Rockville, MD: National Institute
on Drug Abuse, 1983.
Jaffe 1990
Jaffe, J. Drug addiction and drug abuse. In: A Gilman, T
Rall, A Nies, P Taylor editor(s). The pharmacological basis
of therapeutics. 8th Edition. New York: Pergamon Press,
1990:522–573.
Mattick 1993
Mattick R P, Hall W. A treatment outline for approaches
to opioid dependence: Quality assurance project. Canberra:
Australian Government Publishing Service, 1993.
Mattick 1996
Mattick RP, Hall W. Are detoxification programmes
effective?. Lancet 1996;347:97–100.
Ward 1992
Ward J, Mattick R P, Hall W. Key issues in methadone
maintenance treatment. Sydney: New South Wales
University Press, 1992.
∗ Indicates the major publication for the study
7Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dole 1969
Methods Two group,
open, randomised controlled trial.
Randomisation: release dates of treatment applicants were selected by lottery. Applicants who were not
selected and demonstrated motivation for treatment became untreated controls.
Follow-up for 50 weeks.
Participants Geographic region: USA
n = 32 males
mean age = 30 years
15% European descent, 10% African-American, 7% Hispanic
Participants were inmates eligible for release over a four month period from New York City Correctional
Institute for Men.
Eligibility criteria: heroin dependence for 5 or more years, record of 5 or more previous convictions, not
committed to custody of Addiction Services Agency
Interventions Control: wait-list
Treatment: 10 day methadone maintenance pre-release.
Initial dose 10 mg, increasing to 35 mg at release.
Continued methadone maintenance in outpatient clinic after release
Outcomes Urinalysis (weekly for heroin, amphetamines, cocaine, barbituates and alcohol)
Employment / education
Reincarceration
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Gunne 1981
Methods Two group randomised clinical trial.
Randomisation: after eligibility established subjects were randomly allocated to methadone maintenance
or to drug-free treatment
Participants Geographic region: Sweden
Study setting: psychiatric research centre
n = 34, 23.5% female
Eligibility criteria: 20-24 years,
history of at least 4 years IV heroin use, withdrawal signs and positive urine on admission, a minimum of
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Gunne 1981 (Continued)
three completed detoxifications, not arrested or serving a sentence and no dominate abuse of non-opiate
drugs. Exclusion: active infectious disease
Interventions Control: no treatment, could not apply for the methadone program for two years
Treatment: methadone maintenance treatment
Outcomes Illicit drug use / Urinalysis (3 x week)
Criminality
Vocational adjustment
Health
Mortality
Notes 2 controls obtained methadone from private practitioners and were excluded
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Newman 1979
Methods Double blind randomised clinical trial
Randomisation: subjects randomly allocated on discharge from hospital after 2 week stabilisation on 60mg
methadone to detoxification or continued maintenance
Participants Geographic region: Hong Kong
n = 100 males
Study setting: Hospital and outpatient clinic
mean age = 38 years
Eligibility criteria: male, 22-58 years, history of heroin dependence for at least 4 years and at least one
previous treatment, current heroin dependence by three consecutive positive urine samples, voluntary
application for admission (criminal justice referrals excluded), resident with fixed address, absence of past
or present major psychiatric or medical illness
Interventions Treatment: methadone maintenance - flexible dose (average 97 mg / day)
Control: detoxification from 60mg methadone at 1mg/day for 60 days, placebo thereafter
Outcomes Illicit drug use / Urinalysis (daily collection, analysed 2 x week for morphine only)
Retention
Criminal activity
Mortality
Notes
Risk of bias
Item Authors’ judgement Description
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Newman 1979 (Continued)
Allocation concealment? Unclear B - Unclear
Strain 1993a
Methods Three group, double-blind, placebo controlled randomised controlled trial. Patients were stratified by race
and sex and randomly assigned to a fixed dose schedule at admission.
Treatment group assignment, stabilisation dose and dosing schedules were blind to patient and clinic staff
with patient contact
Participants Geographic region: USA
Study setting: methadone treatment research clinic
n = 247
mean age = 34
70% male
50% black
84% unmarried
62% unemployed
Eligibility criteria: 18-50 years, history of IV opioid dependence, no chronic medical illness, absence of
major mental illness, negative pregnancy test and at least three months since last treatment at the clinic
Interventions Initial treatment of active methadone for at least 5 weeks.
15 weeks of stable dosing at 50, 20 or 0 mg per day
Gradual tapering for those receiveing active methadone from weeks 21-26
Individual counselling and group therapy (weekly).
Outcomes Retention
Treatment compliance
Illicit drug use / Urinalysis (collected 3 x weekly, one sample selected at random for analysis for opioids,
cocaine and benzodiazepines)
Notes A subsample of 0mg patients (n=44) received an 8 week induction, reaching 0mg at 9 weeks. Data for
patients in alternate 0mg treatment groups are collapsed
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Vanichseni 1991
Methods Two group, open label, randomised clinical trial, with participants who applied for 45 day methadone
detoxification and had at least six prior treatment episodes were randomly assigned to methadone main-
tenance or detoxification
Participants Geographic region: Thailand
Study setting: narcotics clinic
10Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vanichseni 1991 (Continued)
n = 240 males
Eligibility criteria: heroin injectors applying for 45-day detoxification, at least 6 prior treatment episodes
at the clinic
Interventions Treatment: methadone maintenance (flexible dose, average 74mg)
Control: standard 45 day methadone detoxification
Outcomes Retention
Illicit drug use
Urinalysis (2 x week for opiates)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Yancovitz 1991
Methods Twogroup randomised clinical trial, with opioid dependent participants onwaiting-lists for comprehensive
methadone maintenance programs who were randomised to either the interim methadone program or
wait list with frequent contact
Participants Geographic region: USA
n = 301
Study setting: interim methadone clinic
79.4% male
10% White
35% Black
55% Hispanic
Eligibilty criteria: wait list for comprehensive methadone maintenance program
Interventions Control: wait-list with frequent contact
Treatment: “interim” methadone maintenance; standard physical exam on admission, flexible dosing 5
days a week, pick up on weekends from another site, minimal counselling, referral to community agencies
Outcomes Urinalysis (2 x weekly for heroin and cocaine)
Entry into conventional treatment
Notes For the first 3 months of the study there were three experimental groups; interim methadone, wait-list
with frequent contact and bi-weekly urinalysis, and the wait-list with no contact. Recruitment slowed
which resulted in the protocol being changed two experimental groups; interim methadone and wait-
list with frequent contact. The wait-list then only lasted one month at which time the participants were
switched to a methadone program.
Data from the initial discontinued minimal contact group is not include in the analysis
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Yancovitz 1991 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bale 1980 The authors planned to conduct a randomised controlled trial comparing methadone maintenance, therapeutic commu-
nities and detoxification programs. Ethical and practical problems prevented random assignment and the study therefore
does not meet inclusion criteria for this review
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D A T A A N D A N A L Y S E S
Comparison 1. Methadone maintenance treatment vs no methadone maintenance treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Retention in treatment 3 505 Risk Ratio (M-H, Random, 95% CI) 3.05 [1.75, 5.35]
2 Morphine positive urines 2 409 Risk Difference (M-H, Random, 95% CI) -0.32 [-0.40, -0.23]
3 Self reported heroin use 3 230 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.23, 0.44]
4 Criminal activity 3 363 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.12, 1.25]
5 Mortality 3 435 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.06, 4.23]
Analysis 1.1. Comparison 1 Methadone maintenance treatment vs no methadone maintenance treatment,
Outcome 1 Retention in treatment.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs no methadone maintenance treatment
Outcome: 1 Retention in treatment
Study or subgroup Methadone MT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Newman 1979 38/50 5/50 22.6 % 7.60 [ 3.26, 17.71 ]
Strain 1993a 44/84 17/81 35.2 % 2.50 [ 1.56, 3.99 ]
Vanichseni 1991 91/120 41/120 42.2 % 2.22 [ 1.70, 2.90 ]
Total (95% CI) 254 251 100.0 % 3.05 [ 1.75, 5.35 ]
Total events: 173 (Methadone MT), 63 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 8.01, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 3.91 (P = 0.000092)
0.01 0.1 1 10 100
Favours control Favours Methadone
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Analysis 1.2. Comparison 1 Methadone maintenance treatment vs no methadone maintenance treatment,
Outcome 2 Morphine positive urines.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs no methadone maintenance treatment
Outcome: 2 Morphine positive urines
Study or subgroup MMT Control
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vanichseni 1991 70/120 109/120 66.2 % -0.32 [ -0.43, -0.22 ]
Yancovitz 1991 22/75 56/94 33.8 % -0.30 [ -0.45, -0.16 ]
Total (95% CI) 195 214 100.0 % -0.32 [ -0.40, -0.23 ]
Total events: 92 (MMT), 165 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 7.48 (P < 0.00001)
-1000 -500 0 500 1000
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Methadone maintenance treatment vs no methadone maintenance treatment,
Outcome 3 Self reported heroin use.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs no methadone maintenance treatment
Outcome: 3 Self reported heroin use
Study or subgroup Methadone MT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dole 1969 2/12 15/15 8.3 % 0.20 [ 0.06, 0.61 ]
Gunne 1981 5/17 12/17 16.3 % 0.42 [ 0.19, 0.93 ]
Yancovitz 1991 21/75 83/94 75.5 % 0.32 [ 0.22, 0.46 ]
Total (95% CI) 104 126 100.0 % 0.32 [ 0.23, 0.44 ]
Total events: 28 (Methadone MT), 110 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 6.96 (P < 0.00001)
0.01 0.1 1 10 100
Favours methadone Favours control
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Analysis 1.4. Comparison 1 Methadone maintenance treatment vs no methadone maintenance treatment,
Outcome 4 Criminal activity.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs no methadone maintenance treatment
Outcome: 4 Criminal activity
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dole 1969 3/12 15/16 65.9 % 0.27 [ 0.10, 0.72 ]
Gunne 1981 0/17 2/17 13.9 % 0.20 [ 0.01, 3.88 ]
Yancovitz 1991 2/149 1/152 20.2 % 2.04 [ 0.19, 22.26 ]
Total (95% CI) 178 185 100.0 % 0.39 [ 0.12, 1.25 ]
Total events: 5 (Treatment), 18 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 2.54, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 1.59 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours methadone Favours control
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Analysis 1.5. Comparison 1 Methadone maintenance treatment vs no methadone maintenance treatment,
Outcome 5 Mortality.
Review: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Comparison: 1 Methadone maintenance treatment vs no methadone maintenance treatment
Outcome: 5 Mortality
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gunne 1981 0/17 4/17 31.2 % 0.11 [ 0.01, 1.92 ]
Newman 1979 3/50 1/50 39.6 % 3.00 [ 0.32, 27.87 ]
Yancovitz 1991 0/149 2/152 29.2 % 0.20 [ 0.01, 4.21 ]
Total (95% CI) 216 219 100.0 % 0.49 [ 0.06, 4.23 ]
Total events: 3 (Treatment), 7 (Control)
Heterogeneity: Tau2 = 1.77; Chi2 = 3.89, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 0.65 (P = 0.52)
0.01 0.1 1 10 100
Favours treatment Favours control
WH A T ’ S N E W
Last assessed as up-to-date: 23 February 2003.
Date Event Description
26 March 2008 Amended Converted to new review format.
H I S T O R Y
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Review first published: Issue 4, 2002
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Date Event Description
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